These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 23387800)

  • 1. Cytokine profile and FVIII inhibitors development in haemophilia A.
    Oliveira CA; Velloso-Rodrigues C; Machado FC; Carvalho BN; Gentz SH; Martins-Filho OA; Chaves DG
    Haemophilia; 2013 May; 19(3):e139-42. PubMed ID: 23387800
    [TBL] [Abstract][Full Text] [Related]  

  • 2. New associations: INFG and TGFB1 genes and the inhibitor development in severe haemophilia A.
    de Alencar JB; Macedo LC; de Barros MF; Rodrigues C; Shinzato AH; Pelissari CB; Machado J; Sell AM; Visentainer JE
    Haemophilia; 2015 Jul; 21(4):e312-6. PubMed ID: 25930091
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Cytokine production by CD4+ T cells specific for coagulation factor VIII in healthy subjects and haemophilia A patients.
    Hu G; Guo D; Key NS; Conti-Fine BM
    Thromb Haemost; 2007 May; 97(5):788-94. PubMed ID: 17479189
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune response against serial infusion of factor VIII antigen through an implantable venous-access device system in haemophilia A mice.
    Madoiwa S; Kobayashi E; Kashiwakura Y; Sakata A; Yasumoto A; Ohmori T; Mimuro J; Sakata Y
    Haemophilia; 2012 May; 18(3):e323-30. PubMed ID: 22044430
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Analysis of cytokine genes polymorphism as markers for inhibitor development in haemophilia A.
    Chaves D; Belisário A; Castro G; Santoro M; Rodrigues C
    Int J Immunogenet; 2010 Apr; 37(2):79-82. PubMed ID: 20082647
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A shift towards a T cell cytokine deficiency along with an anti-inflammatory/regulatory microenvironment may enable the synthesis of anti-FVIII inhibitors in haemophilia A patients.
    Chaves DG; Velloso-Rodrigues C; Oliveira CA; Teixeira-Carvalho A; Santoro MM; Martins-Filho OA
    Clin Exp Immunol; 2010 Dec; 162(3):425-37. PubMed ID: 20846164
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Immune regulatory gene polymorphisms as predisposing risk factors for the development of factor VIII inhibitors in Indian severe haemophilia A patients.
    Pinto P; Ghosh K; Shetty S
    Haemophilia; 2012 Sep; 18(5):794-7. PubMed ID: 22630053
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Frequency of factor VIII (FVIII) inhibitor in haemophilia A.
    Borhany M; Kumari M; Shamsi T; Naz A; Farzana T
    J Coll Physicians Surg Pak; 2012 May; 22(5):289-93. PubMed ID: 22538032
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunoglobulin isotypes and functional anti-FVIII antibodies in response to FVIII treatment in Balb/c and C57BL/6 haemophilia A mice.
    Qadura M; Waters B; Burnett E; Chegeni R; Hough C; Othman M; Lillicrap D
    Haemophilia; 2011 Mar; 17(2):288-95. PubMed ID: 21091850
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Low incidence of factor VIII inhibitors in previously untreated patients during prophylaxis, on-demand treatment and surgical procedures, with Octanate®: interim report from an ongoing prospective clinical study.
    Klukowska A; Komrska V; Jansen M; Laguna P
    Haemophilia; 2011 May; 17(3):399-406. PubMed ID: 21118334
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Thrombin generation as objective parameter of treatment response in patients with severe haemophilia A and high-titre inhibitors.
    Luna-Záizar H; Beltrán-Miranda CP; Esparza-Flores MA; Soto-Padilla J; Bergés-García A; Rodríguez-Zepeda MD; Pompa-Garza MT; Jaloma-Cruz AR
    Haemophilia; 2014 Jan; 20(1):e7-14. PubMed ID: 24354488
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Hydrolysis of factor VIII mediated by catalytic antibodies occurs in haemophilia A patients with or without factor VIII inhibitors.
    Grosbois SS; Brionne MF; de Longcamp AL; Gautier P; V Kaveri S; Borel-Derlon A; Repessé Y
    Haemophilia; 2013 Mar; 19(2):322-9. PubMed ID: 23216758
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Mechanisms of action of immune tolerance induction against factor VIII in patients with congenital haemophilia A and factor VIII inhibitors.
    Reipert BM; van Helden PM; Schwarz HP; Hausl C
    Br J Haematol; 2007 Jan; 136(1):12-25. PubMed ID: 17222196
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics and safety of OBI-1, a recombinant B domain-deleted porcine factor VIII, in subjects with haemophilia A.
    Kempton CL; Abshire TC; Deveras RA; Hoots WK; Gill JC; Kessler CM; Key NS; Konkle BA; Kuriakose P; Macfarlane DE; Bergman G
    Haemophilia; 2012 Sep; 18(5):798-804. PubMed ID: 22512291
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Influence of the type of F8 gene mutation on inhibitor development in a single centre cohort of severe haemophilia A patients.
    Gouw SC; Van Der Bom JG; Van Den Berg HM; Zewald RA; Ploos Van Amstel JK; Mauser-Bunschoten EP
    Haemophilia; 2011 Mar; 17(2):275-81. PubMed ID: 21070499
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Successful eradication of a FVIII inhibitor in a 60-year-old patient with mild haemophilia A using single-agent prednisolone.
    Holstein K; Marx G; Lentz B; Bokemeyer C; Langer F
    Hamostaseologie; 2012; 32 Suppl 1():S48-51. PubMed ID: 22960877
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Factor VIII-specific B cell responses in haemophilia A patients with inhibitors.
    van Helden PM; Van Haren SD; Fijnvandraat K; van den Berg HM; Voorberg J
    Haemophilia; 2010 May; 16(102):35-43. PubMed ID: 20536984
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risk of inhibitor development in mild haemophilia A increases with age.
    Mauser-Bunschoten EP; Den Uijl IE; Schutgens RE; Roosendaal G; Fischer K
    Haemophilia; 2012 Mar; 18(2):263-7. PubMed ID: 21851507
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Immune tolerance induction therapy for patients with hemophilia A and FVIII inhibitors particularly using low-dose regimens.
    Lin PC; Liao YM; Tsai SP; Chang TT
    Pediatr Blood Cancer; 2011 Dec; 57(6):1029-33. PubMed ID: 21793191
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Inhibitor development after changing FVIII/IX products in patients with haemophilia].
    Kocher S; Asmelash G; Makki V; Müller S; Krekeler S; Alesci S; Miesbach W
    Hamostaseologie; 2012; 32 Suppl 1():S39-42. PubMed ID: 22961330
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.